Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:333-352. doi: 10.1146/annurev-pharmtox-010919-023537. Epub 2019 Jul 23.

Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.

Author information

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Departments of Obstetrics and Gynecology, and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA; email:


The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields: genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.


big data; drug development; drug repurposing; omics; precision medicine

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center